GB201911403D0 - Conjugate and uses thereof - Google Patents

Conjugate and uses thereof

Info

Publication number
GB201911403D0
GB201911403D0 GBGB1911403.2A GB201911403A GB201911403D0 GB 201911403 D0 GB201911403 D0 GB 201911403D0 GB 201911403 A GB201911403 A GB 201911403A GB 201911403 D0 GB201911403 D0 GB 201911403D0
Authority
GB
United Kingdom
Prior art keywords
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1911403.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB1911403.2A priority Critical patent/GB201911403D0/en
Publication of GB201911403D0 publication Critical patent/GB201911403D0/en
Priority to KR1020227007655A priority patent/KR20220079524A/ko
Priority to AU2020327659A priority patent/AU2020327659A1/en
Priority to EP20754817.3A priority patent/EP4010030A1/en
Priority to PCT/GB2020/051891 priority patent/WO2021028666A1/en
Priority to CN202080071067.8A priority patent/CN114615998B/zh
Priority to US17/631,654 priority patent/US20220275372A1/en
Priority to MX2022001712A priority patent/MX2022001712A/es
Priority to CN202510582562.XA priority patent/CN120837670A/zh
Priority to CA3149700A priority patent/CA3149700A1/en
Priority to BR112022002309A priority patent/BR112022002309A2/pt
Priority to JP2022507761A priority patent/JP7678654B2/ja
Priority to IL290424A priority patent/IL290424A/en
Priority to SA522431627A priority patent/SA522431627B1/ar
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1911403.2A 2019-08-09 2019-08-09 Conjugate and uses thereof Ceased GB201911403D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GBGB1911403.2A GB201911403D0 (en) 2019-08-09 2019-08-09 Conjugate and uses thereof
JP2022507761A JP7678654B2 (ja) 2019-08-09 2020-08-07 複合体及びその使用
US17/631,654 US20220275372A1 (en) 2019-08-09 2020-08-07 Conjugate and uses thereof
CN202510582562.XA CN120837670A (zh) 2019-08-09 2020-08-07 缀合物及其用途
EP20754817.3A EP4010030A1 (en) 2019-08-09 2020-08-07 Conjugate and uses thereof
PCT/GB2020/051891 WO2021028666A1 (en) 2019-08-09 2020-08-07 Conjugate and uses thereof
CN202080071067.8A CN114615998B (zh) 2019-08-09 2020-08-07 缀合物及其用途
KR1020227007655A KR20220079524A (ko) 2019-08-09 2020-08-07 접합체 및 이의 용도
MX2022001712A MX2022001712A (es) 2019-08-09 2020-08-07 Conjugados y usos de los mismos.
AU2020327659A AU2020327659A1 (en) 2019-08-09 2020-08-07 Conjugate and uses thereof
CA3149700A CA3149700A1 (en) 2019-08-09 2020-08-07 Conjugate and uses thereof
BR112022002309A BR112022002309A2 (pt) 2019-08-09 2020-08-07 Conjugado e usos do mesmo
IL290424A IL290424A (en) 2019-08-09 2022-02-07 A bracelet and its uses
SA522431627A SA522431627B1 (ar) 2019-08-09 2022-02-08 متقارن واستخداماته

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1911403.2A GB201911403D0 (en) 2019-08-09 2019-08-09 Conjugate and uses thereof

Publications (1)

Publication Number Publication Date
GB201911403D0 true GB201911403D0 (en) 2019-09-25

Family

ID=67990936

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1911403.2A Ceased GB201911403D0 (en) 2019-08-09 2019-08-09 Conjugate and uses thereof

Country Status (13)

Country Link
US (1) US20220275372A1 (https=)
EP (1) EP4010030A1 (https=)
JP (1) JP7678654B2 (https=)
KR (1) KR20220079524A (https=)
CN (2) CN114615998B (https=)
AU (1) AU2020327659A1 (https=)
BR (1) BR112022002309A2 (https=)
CA (1) CA3149700A1 (https=)
GB (1) GB201911403D0 (https=)
IL (1) IL290424A (https=)
MX (1) MX2022001712A (https=)
SA (1) SA522431627B1 (https=)
WO (1) WO2021028666A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200131231A1 (en) 2017-02-17 2020-04-30 Oxford University Innovation Limited Cell penetrating peptides
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
US12465646B2 (en) 2018-12-07 2025-11-11 Oxford University Innovation Limited Linkers
WO2022171972A1 (en) * 2021-02-12 2022-08-18 Oxford University Innovation Limited Cell-penetrating peptide conjugates and methods of their use
EP4304657A4 (en) * 2021-03-12 2026-04-01 Pepgen Inc METHODS OF TREATMENT OF TYPE 1 MYOTONIC DYSTROPHY USING PEPTIDE-OLIGONUCLEOTIDE CONJUGATES
KR20250116673A (ko) * 2022-11-21 2025-08-01 펩젠 인크. 세포-침투 펩티드, 그의 접합체 및 그의 사용 방법
WO2025033255A1 (ja) * 2023-08-07 2025-02-13 東亞合成株式会社 ペプチドフラグメント及びその利用
WO2025033256A1 (ja) * 2023-08-07 2025-02-13 東亞合成株式会社 ペプチドフラグメント及びその利用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2049664T1 (sl) * 2006-08-11 2012-04-30 Prosensa Technologies Bv Enojna veriga oligonukleotidov, komplementarna repetitivnim elementom, za zdravljenje genetskih bolezni, povezanih z nestabilnostjo dnk ponovitev
WO2009005793A2 (en) * 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2009147368A1 (en) * 2008-06-04 2009-12-10 Medical Research Council Peptides
US20110269665A1 (en) * 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
CN103998458B (zh) * 2011-08-30 2018-10-09 医学研究理事会 具有中央疏水域的细胞穿透肽
EP2900821B1 (en) * 2012-09-25 2020-04-01 Genzyme Corporation Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
RU2708237C2 (ru) 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения

Also Published As

Publication number Publication date
CN114615998A (zh) 2022-06-10
US20220275372A1 (en) 2022-09-01
JP2022543320A (ja) 2022-10-11
JP7678654B2 (ja) 2025-05-16
KR20220079524A (ko) 2022-06-13
CA3149700A1 (en) 2021-02-18
AU2020327659A1 (en) 2022-02-24
EP4010030A1 (en) 2022-06-15
CN114615998B (zh) 2025-05-23
SA522431627B1 (ar) 2024-05-19
BR112022002309A2 (pt) 2022-04-26
CN120837670A (zh) 2025-10-28
WO2021028666A1 (en) 2021-02-18
MX2022001712A (es) 2022-05-13
IL290424A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
IL294052B2 (en) Fluoroalkyl oxadiazoles and their uses
ZA202106612B (en) Compounds and conjugates thereof
IL290424A (en) A bracelet and its uses
IL285148A (en) Diligand drug conjugate and its use
ZA202003833B (en) Conjugates and preparation and use thereof
SG11202101719PA (en) Antibody-drug conjugate and application thereof
SG11202106612QA (en) Improved antibody-oligonucleotide conjugate
IL268102A (en) Anti-GPR 20 antibody and anti-GPR 20 antibody-drug conjugate
PL3794042T3 (pl) Koniugat przeciwciało-lek przeciwciało skierowane przeciwko muc1 - eksatekan
IL285177A (en) compounds and their use
PT3626825T (pt) Anticorpo anti-cdh6 e conjugado anticorpo anti-cdh6-fármaco
IL278877A (en) Amino-pyrazinecarboxamide compounds, conjugates and their uses
IL286497A (en) compounds and their use
GB2591554B (en) Composiitons and methods and uses relating thereto
SG11202101517PA (en) Isoquinoline-steroid conjugates and uses thereof
IL291499A (en) Azaquinoline compounds and their uses
IL287503A (en) Thio-semicarbazide compounds and their use
ZA201905589B (en) Drug-polymer conjugate
SG11202108079RA (en) Compounds and uses thereof
IL284764A (en) compounds and their uses
SG11202009242RA (en) Short conjugated oligoelectrolytes and uses thereof
SG11202008543RA (en) Pyrrolidineamide derivatives and uses thereof
ZA202005144B (en) Parenteral formulations and uses thereof
IL288828A (en) Binding factors - cd38 and their use
EP3266870A4 (en) Conjugate and use thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)